
People Capabilities In this section you can find Services Banking and Finance Banking and Finance overview Asset & Lease Finance Capital Markets Corporate Debt Leveraged Finance Project, Energy and Infrastructure Finance Real Estate Finance Restructuring and Insolvency Securitization and Structured Finance Trade and Export Finance Competition, Trade and Foreign Investment Competition, Trade and Foreign Investment overview Antitrust and Competition Litigation Dawn Raids Foreign Investment and National Security Law International Sanctions and Export Controls International Trade Law Merger Control Procurement and State Aid Construction and Engineering Construction and Engineering overview Construction Disputes Contracts and Procurement EPC Project Advisory Corporate and M&A Corporate and M&A overview Business Development Companies Capital Markets Corporate Governance International Corporate Reorganizations Joint Ventures Mergers and Acquisitions Private Equity Small Business Investment Companies (SBICs) Venture Capital Corporate Crime Corporate Crime overview Anti-Bribery and Corruption Anti-Money Laundering International Sanctions and Export Controls Regulatory Investigations and Enforcement Data Privacy, Security and Technology Data Privacy, Security and Technology overview Congressional Investigations Cybersecurity Data Privacy Disruptive Technology Electronic and Mobile Commerce Information Law Product Counseling Regulatory Defense and Litigation Technology Transactions and Sourcing Telecom Services Employment, Labor and Pensions Employment, Labor and Pensions overview Corporate Transactions Cross-Border Employment and Pensions Diversity, Pay and Discrimination Employee Benefits and Executive Compensation Employment Employment Litigation Global Mobility and Immigration Labor and Industrial Relations Pensions and Retirement Plans Pensions Risk Transfer and Management Environment and Natural Resources Financial Services Regulation Financial Services Regulation overview Asset Management Business Development Companies Crypto Assets Derivatives Financial Services Disputes and Investigations Funds Small Business Investment Companies (SBICs) Insurance Insurance overview Captives Insurance and Reinsurance Disputes Insurance and Retirement Products, Insurance Distribution Insurance Financing and Capital Markets Insurance M&A, Reinsurance and Restructuring Insurance Regulation and Compliance Insurance Regulatory Investigations and Enforcement Insurance Taxation Insurtech Pensions Risk Transfer and Management Intellectual Property Intellectual Property overview IP Audits and Assessments IP Litigation IP Transactional Patents Trademarks, Trade Dress and Copyrights Trade Secrets Investigations Investigations overview Antitrust and Competition Investigations Congressional Investigations Employment Investigations Internal Investigations National Security Investigations Konexo Konexo overview Legal Services Interim Resourcing Data and Cyber Consulting Legal Team Consulting Litigation and Dispute Resolution Litigation and Dispute Resolution overview Antitrust and Competition Investigations Appellate Class Actions Commercial Litigation Construction Disputes Energy Disputes Environmental, Health and Safety Financial Services Disputes and Investigations Fraud Insurance and Reinsurance Disputes International Arbitration Procurement Disputes Professional Liability Real Estate Disputes Regulatory Investigations and Enforcement Securities Enforcement and Litigation Tax Controversy and Litigation Unclaimed Property Real Estate and Planning Real Estate and Planning overview Commercial Development and Leasing Corporate Real Estate Investment Management and Fund Formation Planning and Environmental Real Estate Disputes Real Estate Finance Living Strategic Contracts Strategic Contracts overview Contract Modernization Outsourcing Strategic Partnerships Tax Tax overview Acquisitions and Restructuring Business Taxation Employee Benefits and Executive Compensation Federal Tax Real Estate Tax Taxation of Financial Transactions and Institutions Tax Controversy and Litigation Transfer Pricing US State and Local Tax VAT/Indirect Taxes Industries Agribusiness, Forestry and Climate Solutions Consumer Consumer overview Food and Beverage Hospitality and Leisure Luxury Retail and Wholesale Education Energy Energy overview Clean Energy Electric Cooperatives Energy and Commodities Trading Energy Regulatory Hydrogen Nuclear Oil and Gas Power State Energy Regulatory Group Financial Services Financial Services overview Corporate and Investment Banking Payments and Fintech Private Capital Retail Banking and Consumer Finance Governments and Infrastructure Governments and Infrastructure overview Governments and Strategic Projects Infrastructure Public-private Partnerships Transportation Industrials Industrials overview Aerospace, Defense and Security Automotive Chemicals Manufacturing and Industrial Engineering Life Sciences and Healthcare Life Sciences and Healthcare overview Agriculture and Medicinal Cannabis and CBD Healthcare Industrial Biotechnology Medical Devices Pharmaceuticals and Biotechnology Research and Development Vaccines Real Estate Real Estate overview Alternative Assets Multi and Single Family Residential Office and Industrial Real Estate Investment Retail and Mixed Use Sports Sports overview College Athletics Technology & Digital Technology & Digital overview Digital Content Digital Infrastructure Technology Resources Insights Client tools Events and training Business topics About About us Firm leadership Purpose and values Responsible business Community Diversity, equity and inclusion Environment Pro bono Reports Alumni News Mason Howell Sponsorship Careers US careers Applications Why us? Lawyers and partners Business professionals Students and recent graduates Summer Program LLM Extern Program New attorneys Professional Development Offices United States Visit global site Select a local version of the site Angola Asia Austria Belgium Bulgaria Czech Republic Estonia Finland France Germany Hungary Iraq Ireland Italy Jordan Latvia Lithuania Luxembourg Mauritius Mozambique Netherlands Poland Portugal Qatar Romania Saudi Arabia Slovakia South Africa Spain Sweden Switzerland Tunisia United Arab Emirates United Kingdom United States Rest of the world en Select language Deutsch English Eversheds Sutherland advises Pacira BioSciences, Inc., on its acquisition of GQ Bio Therapeutics Home Resources Insights Home Resources Insights Eversheds Sutherland advises Pacira BioSciences, Inc., on its acquisition of GQ Bio Therapeutics Eversheds Sutherland advises Pacira BioSciences, Inc., on its acquisition of GQ Bio Therapeutics March 03, 2025 GermanyUnited Kingdom GermanyUnited Kingdom GermanyUnited Kingdom Eversheds Sutherland has advised NASDAQ listed Pacira BioSciences, Inc., on its acquisition of the remaining 81 percent equity stake of GQ Bio Therapeutics GmbH. Formats the Html codes.FormatFix the Html to be XHtml compliantFix Write Validate that the text is XHtml compliant.Validate Proofing Eversheds Sutherland advised Pacira BioSciences on the German law aspects of the transaction. Pacira acquired the outstanding stake in GQ Bio from the founders and venture capital investors like High-Tech Gründerfonds and IFB Innovationsstarter GmbH. This transaction builds upon Pacira’s previous investments in GQ Bio, as well as the two companies’ partnership for the development of a commercially scalable manufacturing process for PCRX-201 (enekinragene inzadenovec) and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform. GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity, local-delivery platform that makes genetic medicines more efficient and enables the use of large and multiple gene constructs. GQ Bio also brings to Pacira a preclinical portfolio of assets with disease-modifying potential in prevalent musculoskeletal diseases, and research and development talent. The Eversheds Sutherland team was co-led by Partners Robin Johnson in the UK, Dr. Christian Mense and Dr. Christian Lindner in Germany. The materials on the Eversheds Sutherland website are for general information purposes only and do not constitute legal advice. While reasonable care is taken to ensure accuracy, the materials may not reflect the most current legal developments. Eversheds Sutherland disclaims liability for actions taken based on the materials. Always consult a qualified lawyer for specific legal matters. To view the full disclaimer, see our Terms and Conditions or Disclaimer section in the footer. Services Corporate and M&A Key contacts Robin Johnson Partner United Kingdom Dr. Christian Mense Partner Munich, Germany Dr. Christian Lindner Counsel Munich, Germany Latest Insights legal updates Proposed DFARS Rule on foreign ownership risk mitigation legal updates EU Pay Transparency Directive: Job evaluation and classification guidelines legal updates Global Sustainability & ESG Insights - May 2026 legal updates Tax Bytes: Week of June 8, 2026 Latest News firm news Eversheds Sutherland continues European expansion with further strategic partner hire in project finance client news Eversheds Sutherland powers 12 key deals for Gresham House Energy Storage Fund in three-week surge client news Next stop, public ownership: Eversheds Sutherland advises DfT on GTR transition client news Advising Howden Joinery Group plc on £390m DIY Kitchens acquisition Latest Events virtual \| June 23, 2026 Introduction to Swiss employment law virtual \| September 10, 2026 UAE - Employment law in the Dubai International Financial Centre in-person \| September 17, 2026 Basic foundations of US employment law in-person \| September 23, 2026 2026 BDC Roundtable Tabs Label legal updates June 17, 2026 Proposed DFARS Rule on foreign ownership risk mitigation legal updates June 16, 2026 EU Pay Transparency Directive: Job evaluation and classification guideline... legal updates June 14, 2026 Global Sustainability & ESG Insights - May 2026 legal updates June 12, 2026 Tax Bytes: Week of June 8, 2026 Legal notices Terms & conditions Privacy notice Cookies Disclaimer LinkedIn Facebook YouTube Connect Contact us Client login Staff login Subscribe About us About Eversheds Sutherland Purpose and values Responsible business Alumni Insights Client tools Events and training Business topics Careers Sitemap Offices © 2026 Eversheds Sutherland (US) LLP Eversheds Sutherland is the name and brand under which the members of Eversheds Sutherland Limited (Eversheds Sutherland (International) LLP and Eversheds Sutherland (US) LLP) and their respective controlled, managed or affiliated firms and the members of Eversheds Sutherland (Europe) Limited and Eversheds Sutherland (Africa) Limited (each an "Eversheds Sutherland Entity" and together the "Eversheds Sutherland Entities") provide legal or other services to clients around the world. Eversheds Sutherland Entities are constituted and regulated in accordance with relevant local regulatory and legal requirements. The use of the name Eversheds Sutherland, is for description purposes only and does not imply that the member firms or their controlled, managed or affiliated entities are in a partnership or are part of a global entity. The responsibility for the provision of services to the client is defined in the terms of engagement between the instructed firm and the client. For information on Konexo please also see the Legal Notices page of this website ATTORNEY ADVERTISING - Prior results do not guarantee a similar outcome. Unless otherwise indicated, attorneys at Eversheds Sutherland (US) LLP are not certified by the Texas Board of Legal Specialization.

Eversheds Sutherland advises Pacira BioSciences, Inc., on its acquisition of GQ Bio Therapeutics

March 03, 2025

GermanyUnited Kingdom

Eversheds Sutherland has advised NASDAQ listed Pacira BioSciences, Inc., on its acquisition of the remaining 81 percent equity stake of GQ Bio Therapeutics GmbH.

Formats the Html codes.FormatFix the Html to be XHtml compliantFix Write Validate that the text is XHtml compliant.Validate Proofing

Eversheds Sutherland advised Pacira BioSciences on the German law aspects of the transaction.

Pacira acquired the outstanding stake in GQ Bio from the founders and venture capital investors like High-Tech Gründerfonds and IFB Innovationsstarter GmbH. This transaction builds upon Pacira’s previous investments in GQ Bio, as well as the two companies’ partnership for the development of a commercially scalable manufacturing process for PCRX-201 (enekinragene inzadenovec) and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform.

GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity, local-delivery platform that makes genetic medicines more efficient and enables the use of large and multiple gene constructs. GQ Bio also brings to Pacira a preclinical portfolio of assets with disease-modifying potential in prevalent musculoskeletal diseases, and research and development talent.

The Eversheds Sutherland team was co-led by Partners Robin Johnson in the UK, Dr. Christian Mense and Dr. Christian Lindner in Germany.

The materials on the Eversheds Sutherland website are for general information purposes only and do not constitute legal advice. While reasonable care is taken to ensure accuracy, the materials may not reflect the most current legal developments. Eversheds Sutherland disclaims liability for actions taken based on the materials. Always consult a qualified lawyer for specific legal matters. To view the full disclaimer, see our Terms and Conditions or Disclaimer section in the footer.

Robin Johnson

Partner

United Kingdom

Dr. Christian Mense

Partner

Munich, Germany

christianlindner@eversheds-sutherland.com

Dr. Christian Lindner

Counsel

Munich, Germany

Latest Insights

legal updates
Proposed DFARS Rule on foreign ownership risk mitigation
legal updates
EU Pay Transparency Directive: Job evaluation and classification guidelines
legal updates
Global Sustainability & ESG Insights - May 2026
legal updates
Tax Bytes: Week of June 8, 2026

Latest News

Latest Events

virtual | June 23, 2026
Introduction to Swiss employment law
virtual | September 10, 2026
UAE - Employment law in the Dubai International Financial Centre
in-person | September 17, 2026
Basic foundations of US employment law
in-person | September 23, 2026
2026 BDC Roundtable

Tabs Label

modern office interior glass roof geometry architectural light lines

legal updates

June 17, 2026

Proposed DFARS Rule on foreign ownership risk mitigation

legal updates

June 16, 2026

EU Pay Transparency Directive: Job evaluation and classification guideline...

legal updates

June 14, 2026

Global Sustainability & ESG Insights - May 2026

legal updates

June 12, 2026

Tax Bytes: Week of June 8, 2026

Offices

Eversheds Sutherland is the name and brand under which the members of Eversheds Sutherland Limited (Eversheds Sutherland (International) LLP and Eversheds Sutherland (US) LLP) and their respective controlled, managed or affiliated firms and the members of Eversheds Sutherland (Europe) Limited and Eversheds Sutherland (Africa) Limited (each an "Eversheds Sutherland Entity" and together the "Eversheds Sutherland Entities") provide legal or other services to clients around the world. Eversheds Sutherland Entities are constituted and regulated in accordance with relevant local regulatory and legal requirements. The use of the name Eversheds Sutherland, is for description purposes only and does not imply that the member firms or their controlled, managed or affiliated entities are in a partnership or are part of a global entity. The responsibility for the provision of services to the client is defined in the terms of engagement between the instructed firm and the client. For information on Konexo please also see the Legal Notices page of this website
ATTORNEY ADVERTISING - Prior results do not guarantee a similar outcome.
Unless otherwise indicated, attorneys at Eversheds Sutherland (US) LLP are not certified by the Texas Board of Legal Specialization.

Eversheds Sutherland advises Pacira BioSciences, Inc., on its acquisition of GQ Bio Therapeutics

Services

Key contacts

Latest Insights

Latest News

Latest Events